eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

North AmericaUSBriefs